TY  - BOOK
AU  - Guerrero,Ana
AU  - Innes,Andrew J.
AU  - Roux,Pierre-François
AU  - Buisman,Sonja C.
AU  - Jung,Johannes
AU  - Ortet,Laura
AU  - Moiseeva,Victoria
AU  - Wagner,Verena
AU  - Robinson,Lucas
AU  - Ausema,Albertina
AU  - Potapova,Anna
AU  - Perdiguero,Eusebio
AU  - Weersing,Ellen
AU  - Aarts,Marieke
AU  - Martin,Nadine
AU  - Wuestefeld,Torsten
AU  - Muñoz-Cánoves,Pura
AU  - de Haan,Gerald
AU  - Bischof,Oliver
AU  - Gil,Jesús
TI  - 3-deazaadenosine (3DA) alleviates senescence to promote cellular fitness and cell therapy efficiency in mice
PY  - 2022///-09
KW  - Text
KW  - local
N1  - /pmc/articles/PMC7613850; /pubmed/36438588
N2  - Cellular senescence is a stable type of cell cycle arrest triggered by different stresses. As such, senescence drives age-related diseases and curbs cellular replicative potential. Here, we show that 3-deazaadenosine (3DA), an S-adenosyl homocysteinase (AHCY) inhibitor, alleviates replicative and oncogene-induced senescence. 3DA-treated senescent cells showed reduced global Histone H3 Lysine 36 trimethylation (H3K36me3), an epigenetic modification that marks the bodies of actively transcribed genes. By integrating transcriptome and epigenome data, we demonstrate that 3DA treatment affects key factors of the senescence transcriptional program. Remarkably, 3DA treatment alleviated senescence and increased the proliferative and regenerative potential of muscle stem cells from very old mice in vitro and in vivo. Moreover, ex vivo 3DA treatment was sufficient to enhance the engraftment of human umbilical cord blood (UCB) cells in immunocompromised mice. Together, our results identify 3DA as a promising drug enhancing the efficiency of cellular therapies by restraining senescence
UR  - http://dx.doi.org/10.1038/s43587-022-00279-9
ER  -